Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Paula Katz advises clients on pharmaceutical compliance and enforcement. She joined the firm after serving as Director of Guidance and Policy for the Office of Manufacturing Quality in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). While at the FDA, Ms. Katz focused on current good manufacturing practice (CGMP) enforcement and drug quality policy issues. She advised CDER and FDA leadership regarding manufacturing supply chain controls, contract manufacturing, data and application integrity, administrative law and procedure, and regulatory policy development and enforcement strategy.

  • Advice on FDA inspection responses, including several that successfully resulted in VAI classifications at those sites, interactions with regulatory authorities, and managing compliance and enforcement actions.
  • Conduct investigations into potential GMP or GCP violations.
  • Advice on regulatory issues in their commercial agreements, including ancillary agreements such as Quality Agreements and Pharmacovigilance Agreements.
  • Regularly counsel on drug and biologics recall issues.

Memberships and Affiliations

  • Parenteral Drug Association
  • Food and Drug Law Institute
  • International Society of Pharmaceutical Engineers

Previous Experience

  • U.S. Food and Drug Administration, Director, Manufacturing Quality Guidance and Policy Staff